## Abstract ## Background The use of cholinesterase inhibiors for Alzheimer's disease (AD) is currently being appraised by the National Institute for Clintical Evidence (NICE). This article provides the latest evidence that NICE will be using as part of this appraisal process. ## Objective To pr
โฆ LIBER โฆ
Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model
โ Scribed by Debby Van Dam; Dorothee Abramowski; Matthias Staufenbiel; Peter Paul De Deyn
- Book ID
- 105881086
- Publisher
- Springer
- Year
- 2005
- Tongue
- English
- Weight
- 398 KB
- Volume
- 180
- Category
- Article
- ISSN
- 0033-3158
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
A systematic review of the clinical effe
โ
A. Takeda; E. Loveman; A. Clegg; J. Kirby; J. Picot; E. Payne; C. Green
๐
Article
๐
2005
๐
John Wiley and Sons
๐
English
โ 115 KB
๐ 2 views
Age effects on the regulation of adult h
โ
Sebastian Mirochnic; Susanne Wolf; Matthias Staufenbiel; Gerd Kempermann
๐
Article
๐
2009
๐
John Wiley and Sons
๐
English
โ 568 KB
## Abstract An active lifestyle is to some degree protective against Alzheimer's disease (AD), but the biological basis for this benefit is still far from clear. We hypothesize that physical and cognitive activity increase a reserve for plasticity by increasing adult neurogenesis in the hippocampal